Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: ewolf who wrote (485)	10/25/2005 7:41:19 PM
From: DewDiligence_on_SI	Respond to of 590

It's very possible pani could fail but you're reaching if you think the company is lobbing obvious hints with the cautionary "data supporting" proviso. What else would you expect with a marginally effective therapy? They never attached the data dependent qualifier to their discussions until today. (I’ve listened to every ABGX CC for the past few years.) Moreover, AMGN head of R&D, Roger Perlmutter, made some curious remarks on AMGN’s CC last week that also suggested the data are less than stellar. All this might mean nothing, of course, but as an investor you have play the odds. I do think these nuances imply that the odds of failure have increased to some degree.